Clinical Trial

Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this phase 1 clinical trial is to evaluate the safety, tolerability, and preliminary antitumor activity of a peptide-delivered IL-22BP biotherapy in patients with advanced solid tumors. The main questions it aims to answer are: Is the IL-22BP formulation safe and tolerable? Does the IL-22BP formulation show preliminary antitumor activity?
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-15
Trial Details
NCT Number NCT07583654
Lead Sponsor West China Hospital
Conditions mRNA Vaccine, Solid Tumor Cancer, Peptides, Cancer Metastatic
Enrollment 18 participants
Start Date 2026-07-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14